Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity

Abstract

Histone deacetylases (HDACs) are protein deacetylases that play a role in repression of gene transcription and are emerging targets in cancer therapy. Here, we characterize the structure and enzymatic activity of the catalytic domain of human HDAC7 (cdHDAC7). Although HDAC7 normally exists as part of a multiprotein complex, we show that cdHDAC7 has a low level of deacetylase activity which can be inhibited by known HDAC inhibitors. The crystal structures of human cdHDAC7 and its complexes with two hydroxamate inhibitors are the first structures of the catalytic domain of class IIa HDACs and demonstrate significant differences with previously reported class I and class IIb-like HDAC structures. We show that cdHDAC7 has an additional class IIa HDAC-specific zinc binding motif adjacent to the active site which is likely to participate in substrate recognition and protein-protein interaction and may provide a site for modulation of activity. Furthermore, a different active site topology results in modified catalytic properties and in an enlarged active site pocket. Our studies provide mechanistic insights into class IIa HDACs and facilitate the design of specific modulators.The level of histone acetylation is regulated by the action of two classes of enzymes, histone acetyltransferases and histone deacetylases (HDACs).3 Histone acetyltransferases and HDACs are found in large multiprotein complexes, and recruitment of histone acetylase or deacetylase complexes by coactivators or corepressors is thought to cause a local change in the chromatin structure, resulting in either activation or repression of gene transcription (1). Humans have 18 HDACs and, based on their sequence similarity to yeast factors, they are grouped into four classes (class I-IV). Class II HDACs are homologous to yeast histone deacetylase HDA1 and have been implicated as global regulators of gene expression during cell differentiation and development (2). In humans, class II HDACs are subdivided into classes IIa (HDAC4, HDAC5, HDAC7, and HDAC9) and IIb (HDAC6 and HDAC10). Class IIa HDACs contain two functionally important regions, a highly conserved C-terminal catalytic domain and an N-terminal extension that has no similarity with other proteins, mediates the signal-dependent shuttling between the nucleus and the cytoplasm, and harbors binding sites for transcriptional regulators (2, 3). Class IIa HDACs interact with corepressors such as N-CoR (nuclear receptor corepressor) and the MEF2 (myocyte enhancer factor 2) family of transcription factors that is not only important for controlling gene expression in normal cellular programs like muscle differentiation, T-cell apoptosis, neuronal survival, and synaptic differentiation but has also been linked to cardiac hypertrophy, asthma, atherosclerosis, hypertension, and other pathological conditions (3-5). To date all four class IIa HDACs have been knocked out in mice, and the resulting abnormal phenotypes have been extensively characterized (6 -9). HDAC7 for example, plays an important role in cardiova...

A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity

“…1, is the first FDA-approved pan-HDACi to enter the clinic 10 as a treatment for cutaneous T-cell lymphoma. Crystal structures of human HDAC's with SAHA bound [11][12][13] show the hydroxamic acid coordinated to the active-site zinc (Zn) ion. Several HDACi's have thus been designed based on these data in which their structural motif consists of a metal binding group, a linker domain (that mimics the C a functional group of lysine) that occupies the enzyme's narrow channel and a cap group which interacts with residues on the enzyme surface.…”

Vorinostat-Like Molecules as Structural, Stereochemical, and Pharmacological Tools

“…[5][6][7] To date, detailed biostructural information is available only regarding a few among the known 11 metallo-enzymes. 1,[8][9][10][11] Consequently, the design of isoform-and class-selective inhibitors is somewhat arbitrary and derivative. 1,7,[12][13][14] In addition, complete data regarding the factual HDAC profile for most of the early discovered agents are not available, since the development of effective isozyme-based assays is relatively recent.…”

“…No significant difference was found between the racemic 2 and its individual enantiomers, which proved to be equipotent against all of the zincdependent HDACs. To gain more insight into this equivalence, a docking analysis of the individual enantiomers of 2 was performed based on the crystal structures of HDAC8 8 and HDAC7, 9 which were chosen as representatives of class I and II HDACs, respectively ( Figure 2). 28 In binding these isoforms, a T-shape arrangement was observed for both enantiomers of ligand 2, which projected its aromatic motifs out from the active site channel toward lipophilic pockets located in opposite directions on the enzyme surface.…”

“…30 In part, our hypothesis is also confirmed by a detailed structural comparison between HDAC1 and HDAC8. 31 Considering the high level of conservation of Phe residues among the HDAC isoforms, [8][9][10][11] these interactions might explain the lack of discrimination between the individual enantiomers.…”

A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease

“…The studies by Kao et al also denoted that both HDAC5 and HDAC7 possess multiple repressor domains. The crystal structure of human HDAC7 confirmed that these repressor domains have intricate protein-protein interactions that could modulate its relatively weak deacetylase activity (65). Like HDAC7, full-length HDAC9 is known to colocalize and coimmunoprecipitate with NCoR repressor subunits (61).…”